COMT polymorphisms as predictors of cognitive dysfunction during manic and mixed episodes in bipolar I disorder

Bipolar Disorders

Volumn 14, Issue 5, 2012, Pages 554-564

  Soeiro de Souza, Márcio Gerhardt ^a   Machado Vieira, Rodrigo ^a   Soares Bio, Danielle ^a   Do Prado, Carolina Martins ^a   Moreno, Ricardo Alberto ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Bipolar disorder; Catechol O methyltransferase; Cognition; Depression; Dopamine; Mania

Indexed keywords

CATECHOL METHYLTRANSFERASE;

ADULT; AGE; ALLELE; ARTICLE; ATTENTION; BIPOLAR I DISORDER; BIPOLAR MANIA; COGNITIVE DEFECT; CONTROLLED STUDY; DEPTH PERCEPTION; EDUCATIONAL STATUS; EXECUTIVE FUNCTION; FEMALE; GENDER; GENE FREQUENCY; GENETIC ASSOCIATION; GENOTYPE; HUMAN; INTELLIGENCE TEST; LANGUAGE ABILITY; MAJOR CLINICAL STUDY; MALE; MEMORY; MENTAL PATIENT; MIXED MANIA AND DEPRESSION; MONTGOMERY ASBERG DEPRESSION RATING SCALE; NEUROPSYCHOLOGICAL TEST; PREDICTIVE VALUE; PRIORITY JOURNAL; PSYCHOMOTOR PERFORMANCE; SINGLE NUCLEOTIDE POLYMORPHISM; VERBAL COMMUNICATION; VERBAL MEMORY; VISUAL MEMORY; YOUNG MANIA RATING SCALE;

ADULT; ALLELES; ATTENTION; BIPOLAR DISORDER; CASE-CONTROL STUDIES; CATECHOL O-METHYLTRANSFERASE; COGNITION DISORDERS; DOPAMINE; EXECUTIVE FUNCTION; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; INTELLIGENCE TESTS; MALE; MEMORY; NEUROPSYCHOLOGICAL TESTS; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; PREFRONTAL CORTEX;

EID: 84864383350     PISSN: 13985647     EISSN: 13995618     Source Type: Journal    
DOI: 10.1111/j.1399-5618.2012.01030.x     Document Type: Article

References (65)

1. Solé B, Martínez-Arán A, Torrent C et al. Are bipolar II patients cognitively impaired? A systematic review. Psychol Med 2011; 41: 1791-1803.
2. Thompson JM, Gallagher P, Hughes JH et al. Neurocognitive impairment in euthymic patients with bipolar affective disorder. Br J Psychiatry 2005; 186: 32-40.
3. Quraishi S, Frangou S. Neuropsychology of bipolar disorder: a review. J Affect Disord 2002; 72: 209-226.
4. Savitz J, Solms M, Ramesar R. Neuropsychological dysfunction in bipolar affective disorder: a critical opinion. Bipolar Disord 2005; 7: 216-235.
5. Chaves OC, Lombardo LE, Bearden CE et al. Association of clinical symptoms and neurocognitive performance in bipolar disorder: a longitudinal study. Bipolar Disord 2011; 13: 118-123.
6. Martinez-Aran A, Vieta E, Reinares M et al. Cognitive function across manic or hypomanic, depressed, and euthymic states in bipolar disorder. Am J Psychiatry 2004; 161: 262-270.
7. Bora E, Vahip S, Akdeniz F et al. The effect of previous psychotic mood episodes on cognitive impairment in euthymic bipolar patients. Bipolar Disord 2007; 9: 468-477.
8. Martinez-Aran A, Torrent C, Tabarés-Seisdedos R et al. Neurocognitive impairment in bipolar patients with and without history of psychosis. J Clin Psychiatry 2008; 69: 233-239.
9. Bora E, Yücel M, Pantelis C. Neurocognitive markers of psychosis in bipolar disorder: a meta-analytic study. J Affect Disord 2010; 127: 1-9.
10. James A, Hough M, James S et al. Structural brain and neuropsychometric changes associated with pediatric bipolar disorder with psychosis. Bipolar Disord 2011; 13: 16-27.
11. Levy B, Weiss RD. Neurocognitive impairment and psychosis in bipolar i disorder during early remission from an acute episode of mood disturbance. J Clin Psychiatry 2009; 71: 201-206.
12. Lebowitz BK, Shear PK, Steed MA, Strakowski SM. Verbal fluency in mania: relationship to number of manic episodes. Neuropsychiatry Neuropsychol Behav Neurol 2001; 14: 177-182.
13. López-Jaramillo C, Lopera-Vásquez J, Gallo A et al. Effects of recurrence on the cognitive performance of patients with bipolar I disorder: implications for relapse prevention and treatment adherence. Bipolar Disord 2010; 12: 557-567.
14. Torrent C, Martinez-Aran A, Daban C et al. Effects of atypical antipsychotics on neurocognition in euthymic bipolar patients. Compr Psychiatry 2011; 52: 613-622.
15. Arts B, Jabben N, Krabbendam L, van Os J. A 2-year naturalistic study on cognitive functioning in bipolar disorder. Acta Psychiatr Scand 2011; 123: 190-205.
16. Balanzá-Martínez V, Rubio C, Selva-Vera G et al. Neurocognitive endophenotypes (endophenocognitypes) from studies of relatives of bipolar disorder subjects: a systematic review. Neurosci Biobehav Rev 2008; 32: 1426-1438.
17. Napolitano A, Cesura AM, Da Prada M. The role of monoamine oxidase and catechol O-methyltransferase in dopaminergic neurotransmission. J Neural Transm Suppl 1995; 45: 35-45.
18. Mattay VS, Goldberg TE, Fera F et al. Catechol O-methyltransferase val158-met genotype and individual variation in the brain response to amphetamine. Proc Natl Acad Sci USA 2003; 100: 6186-6191.
19. Lachman HM, Morrow B, Shprintzen R et al. Association of codon 108/158 catechol-O-methyltransferase gene polymorphism with the psychiatric manifestations of velo-cardio-facial syndrome. Am J Med Genet 1996; 67: 468-472.
20. Egan MF, Goldberg TE, Kolachana BS et al. Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia. Proc Natl Acad Sci USA 2001; 98: 6917-6922.
21. Williams GV, Goldman-Rakic PS. Modulation of memory fields by dopamine D1 receptors in prefrontal cortex. Nature 1995; 376: 572-575.
22. Randrup A, Braestrup C. Uptake inhibition of biogenic amines by newer antidepressant drugs: relevance to the dopamine hypothesis of depression. Psychopharmacology 1977; 53: 309-314.
23. Cousins DA, Butts K, Young AH. The role of dopamine in bipolar disorder. Bipolar Disord 2009; 11: 787-806.
24. Zahrt J, Taylor JR, Mathew RG, Arnsten AF. Supranormal stimulation of D1 dopamine receptors in the rodent prefrontal cortex impairs spatial working memory performance. J Neurosci 1997; 17: 8528-8535.
25. Granon S, Passetti F, Thomas KL, Dalley JW, Everitt BJ, Robbins TW. Enhanced and impaired attentional performance after infusion of D1 dopaminergic receptor agents into rat prefrontal cortex. J Neurosci 2000; 20: 1208-1215.
26. Arnsten AFT, Li B-M. Neurobiology of executive functions: catecholamine influences on prefrontal cortical functions. Biol Psychiatry 2005; 57: 1377-1384.
27. Mehta MA, Owen AM, Sahakian BJ, Mavaddat N, Pickard JD, Robbins TW. Methylphenidate enhances working memory by modulating discrete frontal and parietal lobe regions in the human brain. J Neurosci 2000; 20: RC65.
28. Goldman-Rakic PS, Castner SA, Svensson TH, Siever LJ, Williams GV. Targeting the dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction. Psychopharmacology 2004; 174: 3-16.
29. Kimberg DY, D'Esposito M, Farah MJ. Effects of bromocriptine on human subjects depend on working memory capacity. NeuroReport 1997; 8: 3581-3585.
30. Lachman HM, Papolos DF, Saito T, Yu YM, Szumlanski CL, Weinshilboum RM. Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics 1996; 6: 243-250.
31. Käenmäki M, Tammimäki A, Myöhänen T et al. Quantitative role of COMT in dopamine clearance in the prefrontal cortex of freely moving mice. J Neurochem 2010; 114: 1745-1755.
32. Matsumoto M, Weickert CS, Akil M et al. Catechol O-methyltransferase mRNA expression in human and rat brain: evidence for a role in cortical neuronal function. Neuroscience 2003; 116: 127-137.
33. Lotta T, Vidgren J, Tilgmann C et al. Kinetics of human soluble and membrane-bound catechol O-methyltransferase: a revised mechanism and description of the thermolabile variant of the enzyme. Biochemistry 1995; 34: 4202-4210.
34. Weinshilboum RM, Otterness DM, Szumlanski CL. Methylation pharmacogenetics: catechol O-methyltransferase, thiopurine methyltransferase, and histamine N-methyltransferase. Annu Rev Pharmacol Toxicol 1999; 39: 19-52.
35. Savitz J, Solms M, Ramesar R. The molecular genetics of cognition: dopamine, COMT and BDNF. Genes Brain Behav 2006; 5: 311-328.
36. Burdick KE, Funke B, Goldberg JF et al. COMT genotype increases risk for bipolar I disorder and influences neurocognitive performance. Bipolar Disord 2007; 9: 370-376.
37. Bruder GE, Keilp JG, Xu H et al. Catechol-O-methyltransferase (COMT) genotypes and working memory: associations with differing cognitive operations. Biol Psychiatry 2005; 58: 901-907.
38. Malhotra AK, Kestler LJ, Mazzanti C, Bates JA, Goldberg T, Goldman D. A functional polymorphism in the COMT gene and performance on a test of prefrontal cognition. Am J Psychiatry 2002; 159: 652-654.
39. Barnett JH, Scoriels L, Munafò MR. Meta-analysis of the cognitive effects of the catechol-O-methyltransferase gene Val158/108Met polymorphism. Biol Psychiatry 2008; 64: 137-144.
40. Szöke A, Schürhoff F, Méary A et al. Lack of influence of COMT and NET genes variants on executive functions in schizophrenic and bipolar patients, their first-degree relatives and controls. Am J Med Genet B Neuropsychiatr Genet 2006; 141B: 504-512.
41. Wirgenes KV, Djurovic S, Sundet K et al. Catechol O-methyltransferase variants and cognitive performance in schizophrenia and bipolar disorder versus controls. Schizophr Res 2010; 122: 31-37.
42. Bray NJ, Buckland PR, Williams NM et al. A haplotype implicated in schizophrenia susceptibility is associated with reduced COMT expression in human brain. Am J Hum Genet 2003; 73: 152-161.
43. Dempster EL, Mill J, Craig IW, Collier DA. The quantification of COMT mRNA in post mortem cerebellum tissue: diagnosis, genotype, methylation and expression. BMC Med Genet 2006; 7: 10.
44. Tunbridge EM. The catechol-O-methyltransferase gene: its regulation and polymorphisms. Int Rev Neurobiol 2010; 95: 7-27.
45. Campos RN, Costa LF, Bio DS et al. LICAVAL: combination therapy in acute and maintenance treatment of bipolar disorder. Trials 2010; 11: 72.
46. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV Axis I Disorders, Clinical Version (SCID-CV). Washington, DC: American Psychiatric Press, Inc., 1996.
47. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edn (text rev.). Washington, DC: American Psychiatric Association, 2000.
48. Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 1978; 133: 429-435.
49. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134: 382-389.
50. Sheehan DV, Lecrubier Y, Sheehan KH et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998; 59 (Suppl. 20): 22-33;quiz 34-57.
51. Strauss E, Sherman EMS, Spreen O. A Compendium of Neuropsychological Tests. New York: Oxford University Press, 2006.
52. Wechsler D. Wechsler Abbreviated Scale of Intelligence. New York: Psychological Corporation, 1999.
53. Wechsler D. Wechsler Adult Intelligence Scale-Revised. San Antonio: Psychological Corporation, 1981.
54. Lezak MD. Neuropsychological Assessment. New York: Oxford University Press, 2004.
55. Laitinen J, Samarut J, Hölttä E. A nontoxic and versatile protein salting-out method for isolation of DNA. Biotechniques 1994; 17: 316, 318, 320-322.
56. Shifman S, Bronstein M, Sternfeld M et al. A highly significant association between a COMT haplotype and schizophrenia. Am J Hum Genet 2002; 71: 1296-1302.
57. Shifman S, Bronstein M, Sternfeld M et al. COMT: a common susceptibility gene in bipolar disorder and schizophrenia. Am J Med Genet B Neuropsychiatr Genet 2004; 128B: 61-64.
58. Tsai S-J, Yu YW-Y, Chen T-J et al. Association study of a functional catechol-O-methyltransferase-gene polymorphism and cognitive function in healthy females. Neurosci Lett 2003; 338: 123-126.
59. Sprague RL, Sleator EK. Methylphenidate in hyperkinetic children: differences in dose effects on learning and social behavior. Science 1977; 198: 1274-1276.
60. Jacobs D, Silverstone T. Dextroamphetamine-induced arousal in human subjects as a model for mania. Psychol Med 1986; 16: 323-329.
61. Post RM, Jimerson DC, Bunney WE, Goodwin FK. Dopamine and mania: behavioral and biochemical effects of the dopamine receptor blocker pimozide. Psychopharmacology 1980; 67: 297-305.
62. Erfurth A, Michael N, Stadtland C, Arolt V. Bupropion as add-on strategy in difficult-to-treat bipolar depressive patients. Neuropsychobiology 2002; 45 (Suppl. 1): 33-36.
63. Jacobs D, Silverstone T. Dextroamphetamine-induced arousal in human subjects as a model for mania. Psychol Med 1986; 16: 323-329.
64. Post RM, Gerner RH, Carman JS et al. Effects of a dopamine agonist piribedil in depressed patients: relationship of pretreatment homovanillic acid to antidepressant response. Arch Gen Psychiatry 1978; 35: 609-615.
65. Bilder RM, Volavka J, Lachman HM, Grace AA. The catechol-O-methyltransferase polymorphism: relations to the tonic-phasic dopamine hypothesis and neuropsychiatric phenotypes. Neuropsychopharmacology 2004; 29: 1943-1961.